Drugs / allogeneic donor derived B-lymphocytes
allogeneic donor derived B-lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02007811 | Nov 2013 → Dec 2015 | Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, aplastic anemia +3 | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic donor derived B-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02007811 ↗ |
| Modality | Cell therapy | “new cellular therapy with B-lymphocytes” NCT02007811 ↗ |